Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 5/20 | 0.35 |
| ▸ | BTK | Q06187 | 4/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30736078 | 0.92 | FGFR4 (0.46) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL31745544 | 0.91 | FGFR4 (0.48) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL31745425 | 0.89 | BTK (0.39) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL30791519 | 0.81 | FGFR1 (0.48) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL30306035 | 0.81 | CYP3A4 (0.54) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL29002680 | 0.81 | CYP3A4 (0.54) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL30736176 | 0.81 | BTK (0.39) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL30736171 | 0.81 | CYP3A4 (0.60) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL31745511 | 0.80 | BLK (0.39) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 | |
| SCHEMBL31745548 | 0.79 | BTK (0.38) | FGFR4CYP3A4CYP2D6FGFR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LTD (HK) | 2025-12-18 | — | — | US | disclosed |
| EP-4547669-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024002157-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382297-A1 | INHIBITORS OF FGFR2 AND FGFR3 AND USES THEREOF | FGFR3, FGFR2, FGFR1 | FGFR4 4/4885CYP3A4 4297/4885CYP2D6 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.